Research on biomarkers in "A randomized phase II study to investigate the deepness of response of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors"

Research on biomarkers in "A randomized phase II study to investigate the deepness of response of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors" - JACCRO CC-13AR

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018412

Enrollment

300

Registered

2015-07-27

Start date

2015-07-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

FOLFOXIRI+/-Bevacizumab (To 12 courses) 5-FU+Levofolinate+/-Bevacizumab (From 13 courses) Bevacizumab 5mg/kg/bi-weekly Irinotecan 150mg/m2/bi-weekly Oxaliplatin 85mg/m2/bi-weekly Levofolinate 200

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are registered in JACCRO CC-13 study (UMIN000018217) and eligible to this research. (1) Approved to supply the section for this research by IRB. (2) Written informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients who are regarded as inadequate for study enrollment by investigators. (2) Patients who refuse to supply the section.

Design outcomes

Primary

Measure	Time frame
Correlation between the reported biomarkers or outcome and clinical response.	—

Secondary

Measure	Time frame
Correlation between the new biomarkers or outcome and clinical response.	—

Countries

Japan

Contacts

Public ContactMasashi Fujii

Japan Clinical Cancer Research Organization Office

masashi.fujii@gioncology.jp03-5579-9882

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Research on biomarkers in &quot;A randomized phase II study to investigate the deepness of response of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors&quot;